Attached files
Exhibit 32.1
CERTIFICATION OF INTERIM CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002
In
connection with the Quarterly Report of Tenax Therapeutics, Inc.
(the “Company”) on Form 10-Q for the period ended June
30, 2017 as filed with the Securities and Exchange Commission on
the date hereof (the “Report”), I, Michael B. Jebsen,
Interim Chief Executive Officer and Chief Financial Officer
(Principal Executive and Financial Officer) of the Company, certify
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002,
that:
(1) the
Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and
(2) the
information contained in the Report fairly presents, in all
material respects, the financial condition and results of
operations of the Company.
Date:
August 9, 2017
|
/s/ Michael B.
Jebsen
|
Michael B.
Jebsen
|
Interim Chief Financial Officer, President and Chief Financial
Officer
(Principal Executive and Financial Officer)
|
The
foregoing certification is being furnished solely to accompany the
Report pursuant to 18 U.S.C. Section 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the
date hereof, regardless of any general incorporation language in
such filing.
A
signed original of this written statement required by Section 906
of the Sarbanes-Oxley Act of 2002 has been provided to the Company
and will be retained by the Company and furnished to the Securities
and Exchange Commission or its staff upon request
.